Transcript:
Yi-Bin Chen, MD: Welcome to this Cancer Network presentation, Developments in Graft versus Host Disease Prevention and Treatment. I am your host, Dr Yi-Bin Chen. I am the director of the hematopoietic cell transplant and cell therapy program and the Rogers Endowed Chair at Massachusetts General Hospital and associate professor of medicine at Harvard Medical School in Boston. Joining me today are my friends and colleagues, Drs Amin Alousi, Nelson Chao, and Hana Safah. Would you introduce yourselves? Nelson, go ahead.
Nelson J. Chao, MD, MBA: I am Nelson Chao. I run the hematology malignancy and cell therapy program at Duke University in Durham, North Carolina.
Yi-Bin Chen, MD: Amin?
Amin M. Alousi, MD: Thank you, Yi-Bin. I am Amin Alousi, professor of medicine at The University of Texas MD Anderson Cancer Center in Houston, and I lead our GVHD [graft versus host disease] program multidiscipline clinic and long-term follow-up. I am the medical director.
Yi-Bin Chen, MD: Hana?
Hana F. Safah, MD: Thank you. I am Dr Safah. I am a professor of medicine at Tulane School of Medicine in New Orleans, Louisiana, and I am the director of the stem cell transplant program, as well as the hematology malignancy program at Tulane.
Yi-Bin Chen, MD: Today we are going to review background information on hematopoietic cell transplants, specifically focusing on graft vs host disease. We will review treatment options, recent development, and future direction. Well review a couple of clinical scenarios and discuss the information that we are all using in the clinic to make treatment decisions.Hematopoietic cell transplantation is something that none of us take likely. I think all of our centers perform a good number of these transplants every year, and the numbers are increasing. Its interesting to think about because not everyone understands why we do transplants and how that is interlaced with this complication of graft versus host disease. Nelson, do you want to talk a little bit about the underlying mechanism of how transplant helps patients, and how that relates to GVHD?
Nelson J. Chao, MD, MBA: Sure. Transplant is the first immunotherapy that we have. It was probably 45 plus years ago when it became pretty clear that you could alter somebodys immune system with new bone marrow cells. When we do a bone marrow transplant, there tends to be 3 components: you have to ablate the recipient so there is no rejection, give the stem cells with hematopoiesis, and then because of hematopoiesis, you actually replace the immune system. The immune system is a big component of the transplant. You give the preparatory regimen to treat the underlying disease, but the immune system thats new also can cause what we call graft versus leukemia [GVL] or graft versus tumor effect [GVTE], which is recognizing the host tumor as foreign and getting rid of it. That piece, graft versus leukemia, has a counterpart that is graft versus host [GVH]. Just as leukemia can be formed to the donor cells, host tissue can be formed to the donor cells as well and cause disease we call graft versus host.
Yi-Bin Chen, MD: When I was first training, I was always told that the holy grail in what we do in transplant is finding a way to separate this graft versus leukemia from graft versus host disease. I think weve made a lot of efforts , trying to do that over the past few decades, but Im not sure if they have been super successful. I think that recent work may be starting to do that. I think if you look at where we used to be with transplant back in the 1970s, when this all started or actually gained more popularity, youll see there is so much more heterogeneity these days. All of us use a lot of different graft sources. Hana, do you want to talk about the different sources of hematopoietic stem cells that we use these days? And maybe how that has changed over the past few years in terms of popularity?
Hana F. Safah, MD: Of course. The easiest one to speak of is where the stem cell is coming from the peripheral blood versus the bone marrowbut there is also the umbilical cord. As a transplanter of adult stem cells, I use the cord in a very few instances; it is more common when it comes to using stem cell transplant in the pediatric state. But mostly, it is the peripheral blood versus the bone marrow. With each 1 of those stem cell source and grafts, there are complications that we expect, especially when we are talking about GVHD and mainly chronic GVHD. That has been shown in studies. Data are available that support that with bone marrow stem cells, there is less chronic GVHD and a smaller burden of chronic GVHD on the patients after stem cell transplantation, as well as better recovery and quality of life. However, having said that, between them there isnt a difference in relapse and overall survival [OS]. Keep that in mind.
Now, first we go through the match-related then we go to the donor themselves. When you look at the donors, you have the match related or the match unrelated. There is mismatch related and there is mismatch unrelated. When we talk about the mismatch related, we are talking mostly about the haploidentical, which is becoming the newest fashion in stem cell transplant. We have learned so much from doing haploidentical stem cell transplants especially when it comes to learning how to take care of GVHD and the effect of treatment that is being applied for haploidenticaland now it is being used in trials, as well as being used by us in practice to take care of GVHD when we deal with match unrelated or mismatch unrelated.
Yi-Bin Chen, MD: Again, when I first trained and I think thats true for all of usI used to take into account the patients donor options to think about a transplant. These days, we accept the transplant if youre a match sibling, match unrelated donor, mismatch unrelated donor, haploidentical donor, or if youre using umbilical cord blood. Amin, do we have any data that say that a certain type of donor works best, or whatever that means in terms of overall outcomes? Or is there an algorithm you use at MD Anderson when youre trying to figure this out?
Amin M. Alousi, MD: Yes, data are still coming in and evolving, but in terms of algorithms at MD Anderson and elsewhere, we still say match-related donors are the top of that algorithm and would be the first donor of choice. The reason for that is because numerous studies have shown lower rates of graft versus host disease and treatment related mortality. In some settings, that may not always be the case. There are data to suggest that if a patient has advanced disease or high-risk disease, that may not apply. There are some conflictingdata to suggest benefits, or lack thereof, if donors are ofolder age, match sibling versus younger age match. There is analysis that we did anumber of years ago within the CIBMTR[Center for International Blood and Marrow Transplant Research] that showed that an older match sibling still has a better algorithm versus an unrelated transplant with regard to complications in GVHD, treatment-related mortality, and overall mortality. Some recent data suggest that in MDS [myelodysplastic syndromes]. Thats no longer the case, but generally speaking, a match related donor is still the preferred donor of the choice. Once you get away from that, there are a number of analyses that suggest comparable outcomes for half-match or haploidentical family member donors as match-term related donors.Data increasingly suggest that outcomes of even mismatch-related donors can be comparable, provided the right type of graft versus host disease prophylaxis is employed in those strategies.
Transcript edited for clarity.
See more here:
GVHD in the Context of Stem Cell or Allogeneic Transplant - Cancer Network
- Cardiovascular Glossary A-Z (All) | Texas Heart Institute - January 4th, 2023
- ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022) - Business Wire - September 25th, 2022
- De-extinction Company Aims to Resurrect the Tasmanian Tiger - Scientific American - August 22nd, 2022
- Dean Kamen on the power of celebrating your own obsoletion - TechCrunch - July 27th, 2022
- Westin and Sehn Carve Out the Role of CAR T-Cell Therapy and Transplant in Primary Refractory DLBCL - OncLive - July 27th, 2022
- Unanticipated findings cast new light on the genetic regulation of different brain tumors - Baylor College of Medicine - July 27th, 2022
- Chaotic response in Uvalde, Parkland shooter faces death penalty, mall shooting leaves 3 dead and jury selection begins in Bannon trial | Hot off the... - July 19th, 2022
- Stem Cells, Abortion, Baby Parts, & the Ukraine - Physicians for Life - June 22nd, 2022
- INVECTYS, MD ANDERSON AND CTMC ANNOUNCE STRATEGIC COLLABORATION FOR CAR T CELL THERAPY DEVELOPMENT - BioSpace - June 22nd, 2022
- Quizartinib Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy in Patients with Newly Diagnosed FLT3-ITD Positive... - June 13th, 2022
- Texas Family Fights to Access $2.1 Million Treatment for Baby - NBC 5 Dallas-Fort Worth - May 15th, 2022
- La Conner native raising funds to cure blood cancer - La Conner Weekly News - May 2nd, 2022
- CORRECTING and REPLACING -- Affimed NV - GlobeNewswire - May 2nd, 2022
- StudyFinds Blotter: Other Notable Health Research From April 28, 2022 - Study Finds - May 2nd, 2022
- Sung to lead cancer institute; Bankston wins fellowship - ASBMB Today - April 19th, 2022
- Houston teen first in Texas to become own donor to reverse sickle cell anemia - FOX 26 Houston - March 25th, 2022
- Oleic Acid, a Key to Activating the Brains Fountain of Youth - Neuroscience News - March 25th, 2022
- Stem Cell Therapy Boosts Outcomes for Some Heart Failure Patients - HealthDay - November 22nd, 2021
- Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed... - November 22nd, 2021
- BioBridge Global continues history of innovation with umbilical cord collection and processing under cGMP standards for further manufacture - Yahoo... - November 22nd, 2021
- Immatics to Present Update on Lead ACTengine Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancers 36th Annual Meeting - Yahoo... - November 8th, 2021
- Affimed Announces Poster Presentations at the 63rd American Society of Hematology Annual ... - Tyler Morning Telegraph - November 8th, 2021
- ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting - StreetInsider.com - November 8th, 2021
- The Power of the Immune System: New Treatment for Painful Blood Cancer Side Effect - Curetoday.com - October 28th, 2021
- Durham firm offering up to $10,000 for researchers to use its intestinal technology - WRAL Tech Wire - October 16th, 2021
- Elevated cryptic transcription emerges as a common theme in aging mammalian cells - Baylor College of Medicine News - August 31st, 2021
- Insulin-producing implants are being developed to control Type 1 diabetes - Health Europa - August 5th, 2021
- Cryptic Transcription in Mammalian Stem Cells Linked to Aging - Technology Networks - August 5th, 2021
- Overview of DLBCL - Targeted Oncology - August 5th, 2021
- The True Crime Junkies and the Curious Case of a Missing Husband - VICE - August 5th, 2021
- FROM THE LABS: Hispanic Heritage Spotlight: Interview with Dr. Nino Rainusso - Baylor College of Medicine News - November 13th, 2020
- UPMC nurse practitioner hailed 'healthcare hero' on live TV - Altoona Mirror - October 31st, 2020
- BrainStrom Cell Therapeutics (NASDAQ:BCLI) Enters Agreement With Catalent (NYSE:CTLT) For Manufacture Of Its NurOwn Cell Therapy - BP Journal - October 31st, 2020
- Dr. Daisy Ayim, Cosmetic Surgeon, ObGyn, Business Owner and Entrepreneur, Is Revolutionizing The Integration Of Women's Health And Cosmetic Care -... - October 31st, 2020
- Five Indian American Researchers Named Among NIH 2020 New Innovator Awardees - India West - October 21st, 2020
- Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma - Science... - October 21st, 2020
- Biotechnology could change the cattle industry. Will it succeed? - Salon - September 8th, 2020
- STEM CELLS | VitaDrip IV Therapy | Texas - June 26th, 2020
- New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring's Plinabulin - BioSpace - June 23rd, 2020
- Tau: Why Alzheimer's Worsens Fast in Some, Slowly in Others - Alzforum - June 23rd, 2020
- Scholarly Perspectives on COVID-19, Part 1: This Was Only a Matter of Time - Southern Newsroom - June 23rd, 2020
- Texas Stem Cell Law Opens Door for Controversial Treatments - June 11th, 2020
- Who's to blame? These three scientists are at the heart of the Surgisphere COVID-19 scandal - Science Magazine - June 9th, 2020
- FTC ramps up enforcement with new wave of warning letters - NutraIngredients-usa.com - June 9th, 2020
- UT Student Awarded Prestigious Astronaut Scholarship - UT News | The University of Texas at Austin - June 9th, 2020
- South Sound Community Bands Together To Save Local Lives - southsoundtalk.com - May 7th, 2020
- Pfizer, NYU working on innovative coronavirus vaccine that could be ready by end of summer - NBC News - May 7th, 2020
- How industry hopes to take on COVID-19 - Bioprocess Insider - BioProcess Insider - March 8th, 2020
- Meng Hsieh, Andrew Shubin - The New York Times - March 8th, 2020
- Jimbo Fisher's Kidz1stFund, Aggie Corps of Cadets team up for Be the Match bone marrow donor registry drive - Bryan-College Station Eagle - March 2nd, 2020
- Texas A&M Researcher Named To National List Of Inspiring Black Scientists - Texas A&M University - March 2nd, 2020
- What to do in Madison: March 2-8, 2020 - The Bozho - March 2nd, 2020
- Cumberland County family turns to non-FDA approved stem cell treatment to help two-year-old son with cerebral palsy - FOX43.com - February 27th, 2020
- Recombinetics Announces Collaboration with University of Texas Southwestern to Advance Regenerative Medicine Through Therapeutic Cell, Tissue, and... - February 27th, 2020
- Stem Cell Therapy for Joints & Spine in Austin Texas - January 28th, 2020
- El Paso scientists to deliver 3D bioprinted miniature hearts to the ISS - 3D Printing Industry - January 28th, 2020
- El Paso scientists team up for heart research project at the International Space Station - KVIA El Paso - January 28th, 2020
- Drugs, Biologics, and Regenerative Medicine in 2019: A Successful Year Ends with Promise of a More Challenging 2020 - JD Supra - December 18th, 2019
- Incoming Faculty Bring New Areas of Research to Rensselaer - Rensselaer Polytechnic Institute - September 24th, 2019
- Nivolumab as an addition to frontline therapy of AML in younger patients - AML Global Portal - September 24th, 2019
- Interview: BIOLIFE4D is The First US Company to Bioprint a Mini-Heart (for Cardiotoxicity Testing) - 3DPrint.com - September 24th, 2019
- Stem cells regrow leg's long bones - WNDU-TV - September 22nd, 2019
- A breakthrough in the battle against citrus greening - Gainesville Sun - September 22nd, 2019
- Comparing Mymetics (OTCMKTS:MYMX) & Crispr Therapeutics (OTCMKTS:CRSP) - TechNewsObserver - September 22nd, 2019
- STEM CELL THERAPY & TREATMENTS Texas Regional Health - September 10th, 2019
- Fast Facts: Stem Cells 101 Vital Record - September 10th, 2019
- Keller, TX Stem Cells | Neuropathy & Pain Centers of Texas - May 31st, 2019
- Arlington Stem Cells | Neuropathy & Pain Centers of Texas - May 1st, 2019
- Houston, Texas Stem Cell Transplants, Richmond, Sugar Land ... - April 21st, 2019
- Fort Worth Stem Cells | Neuropathy and Pain Centers of Texas - April 15th, 2019
- Stem Cell Rejuvenation Therapy | Totalhormonegenetherapy.com - April 15th, 2019
- Our Doctors - Knee Stem Cells - March 17th, 2019
- Stem Cell Treatment Center in Dallas, Texas | Stem Cell ... - March 17th, 2019
- Neuropathy & Pain Centers of Texas - Stem Cells & Neuropathy - February 6th, 2019
- Stem Cell Doctor Dallas Dr. Darcy Brunk | Dallas, Plano ... - January 25th, 2019
- Four Types of Stem Cells - Texas Right to Life - December 15th, 2018
- Texas | The Stem Cellar - December 5th, 2018
- Dallas, Texas, Stem Cells Treatment, Legal, Ft. Worth ... - November 16th, 2018
- HB810 | Right to Try Law | Texas Stem Cell Law | StemGenex - October 13th, 2018
- Shooting Up Stem Cells With Ben Greenfield The Down The ... - September 16th, 2018